Showing 1601-1610 of 4166 results for "".
Why Now Is a Good Time to Buy a Private Practice
https://modernod.com/topics/business/why-now-is-a-good-time-to-buy-a-private-practice/38889/Early career ODs may want to consider taking advantage of a favorable buying market.Lumithera CEO Discusses FDA Authorization for Veleda for Dry AMD
https://modernod.com/podcasts/eyewire-news-the-podcast/lumithera-ceo-discusses-fda-authorization-for-veleda-for-dry-amd/37059/The CEO of Lumithera joins us to discuss the FDA authorization of the Veleda system for dry AMD; the FDA accepts the resubmitted NDA for dry eye disease candidate reproxalap; and Alcon launches the first contact lens designed for a 1-week replacement cycle.84. Case Reflection: Contact Lens Abuser
https://modernod.com/podcasts/four-eyes/84-case-reflection-contact-lens-abuser/37034/In this episode of our New Grad Case Reflection series, we dive into the challenges of managing a patient who consistently abused their contact lens wear. Patient education on contact lens hygiene is vital, but what happens when they ignore your advice? Join Dr. Bilkhu as she reflects on her experieBreaking News From the AAO Meeting in Chicago
https://modernod.com/podcasts/eyewire-news-the-podcast/breaking-news-from-the-aao-meeting-in-chicago/37055/Eyewire News: The Podcast reports on new products and breaking news live from the American Academy of Ophthalmology meeting in Chicago.What’s Hot in Heat Therapy for OSD
https://modernod.com/videos/eye-care-insiders/eye-care-insiders-oct-2024-video/37349/Joseph J. Allen, OD, FAAO, Dipl ABO, takes a look at the plethora of options available for treating ocular surface disease with a warm compress. He offers important reminders to share with patients, reviews recent data to back up your recommendations, and groups the products into different categorieB+L Receives FDA Approval for enVista Envy IOL
https://modernod.com/podcasts/eyewire-news-the-podcast/bl-receives-fda-approval-for-envista-envy-iol/37054/Bausch + Lomb receives FDA approval for a new IOL on its enVista platform; Nanoscope advances it gene therapy for retinitis pigmentosa; and Orasis completes a major funding round to support the launch of its presbyopia eye drop.Your Great-Grandkids May Not Live Past 100
https://modernod.com/articles/significant-findings/your-great-grandkids-may-not-live-past-100/37807/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatAldeyra Resubmits NDA for DED Drug Reproxalap
https://modernod.com/podcasts/eyewire-news-the-podcast/aldeyra-resubmits-nda-for-ded-drug-reproxalap/37053/Aldeyra resubmits its NDA for dry eye drug reproxalap; Clearside announces new phase 2b topline data for its investigational extended-release wet AMD drug; and Bausch + Lomb launches a new digital e-commerce marketplace.Treating Dry Eye at the Molecular Level
https://modernod.com/podcasts/to-the-point/treating-dry-eye-at-the-molecular-level/36939/Jacob Lang, OD, FAAO, shares his knowledge of innovative therapies for dry eye with Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, MBA, MS, FAAO. He discusses drugs in development that target pathways involved in ocular surface disease, such as reactive aldehyde species inhibitors, transient receLife in the Dry Eye Lane
https://modernod.com/topics/ocular-surface/life-in-the-dry-eye-lane/38875/A practice focused exclusively on dry eye benefits both the practitioner and patients.